Disappointment struck Biogen (BIIB 0.12%) -- one of the best performing big biotech stocks of 2012 -- yesterday after the company announced that its experimental ALS drug failed its phase 3 clinical trial. This is sad news for ALS patients, but multiple sclerosis patients and Biogen investors are now looking toward the potential approval from the Food and Drug Administration for the company's drug BG-12. In this video, our analysts discuss the recent news and also give an overview of Biogen's potential position in the MS drug market.
2013 Focus for Biogen Investors
By Max Macaluso and Brenton Flynn – Jan 4, 2013 at 6:00PM
NASDAQ: BIIB
Biogen
Market Cap
$22B
Today's Change
(-0.12%) $0.18
Current Price
$149.90
Price as of October 24, 2025 at 3:58 PM ET
With Biogen's recent clinical trial failure, what should investors focus on now?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo